Germany

Germany's health product regulation is governed by a multi-authority framework. The Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) is the primary federal authority responsible for pharmaceuticals and medical devices, while the Paul-Ehrlich-Institut (PEI) oversees vaccines, blood products, and advanced therapy medicinal products (ATMPs). The European Medicines Agency (EMA) serves as the supranational authority for centralized marketing authorization procedures applicable across all EU member states. Pharmaceuticals may enter the German market via four routes: the EMA Centralized Procedure (CP), the Mutual Recognition Procedure (MRP), the Decentralized Procedure (DCP), or the national procedure administered by BfArM. Medical devices are regulated under EU Regulation 2017/745 (MDR) and diagnostics under EU Regulation 2017/746 (IVDR), requiring CE marking via Notified Bodies rather than direct BfArM approval. Digital health applications (Digitale Gesundheitsanwendungen, DiGA) follow a fast-track pathway through BfArM under the DVG (Digital Supply Act), allowing provisional listing within 90 days.

All marketing authorization applications for pharmaceuticals must follow the Common Technical Document (CTD) format in line with ICH guidelines, and submissions are accepted in English for EU-level procedures. A locally established EU-based Qualified Person for Pharmacovigilance (QPPV) and an EU marketing authorization holder are mandatory. Germany has been an active implementer of the EU Joint Clinical Assessment (JCA) framework introduced under EU Regulation 2021/2282, which standardizes early health technology assessment (HTA) for certain new medicines and medical devices across member states. Post-Brexit, Germany has reinforced its reliance on EMA procedures for cross-border market access. The DiGA pathway represents a notable regulatory innovation, enabling digital therapeutics to gain reimbursement eligibility following a structured evidence assessment by BfArM, with provisional approval permissible while real-world evidence is gathered.

Germany operates a statutory health insurance (Gesetzliche Krankenversicherung, GKV) system covering approximately 90% of the population, administered through more than 95 non-profit sickness funds (Krankenkassen) regulated by the Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) and overseen by the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). Pharmaceutical pricing and reimbursement are governed by the Act on the Reform of the Market for Medicinal Products (AMNOG, 2011), under which all newly approved medicines with added therapeutic benefit undergo mandatory early benefit assessment (frühe Nutzenbewertung) by the G-BA within 12 months of market launch, followed by price negotiations between the manufacturer and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband). Medical devices and diagnostics are reimbursed through the GKV benefits catalogue (EBM for outpatient, DRG for inpatient), with coverage decisions coordinated by the G-BA. Hospital procurement is decentralized across 16 federal states (Länder), with individual hospital networks and group purchasing organizations (GPOs) conducting their own tender processes, often aggregated through procurement consortia.

Germany's private health insurance sector (Private Krankenversicherung, PKV) covers approximately 10% of the population and generally reimburses products and services without the same HTA restrictions as the GKV system, offering an additional market access channel for premium-priced innovations. Germany is a high-income country and does not typically participate in donor-funded procurement mechanisms such as UNICEF Supply Division, the Global Fund, USAID, or Gavi, which are oriented toward low- and middle-income country markets. However, Germany is a major donor contributor to these organizations and participates in EU-level joint procurement initiatives, most notably the EU Joint Procurement Agreement (JPA) for pandemic countermeasures, through which Germany co-procures vaccines and medical countermeasures with other EU member states. There are no formal local manufacturing preference policies mandating domestic sourcing, though Germany's national pharmaceutical strategy (Pharma-Strategie) and EU open strategic autonomy initiatives increasingly incentivize European supply chain resilience and domestic active pharmaceutical ingredient (API) production capacity.